Plain-English translation of NCT03755739 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial compares two ways of giving immunotherapy drugs like Pembrolizumab to treat advanced cancers. One approach delivers the medication directly into or near the tumor using a special needle or small tube placed by a doctor, while the standard approach injects it into a vein. Researchers believe sending the medication straight to the cancer may work better and cause fewer side effects.
Many advanced cancers don't respond well enough to standard immunotherapy given through the vein, and doctors need better treatment options. By delivering this medication directly to the tumor, doctors hope to achieve higher drug concentrations at the cancer site, improve effectiveness, and reduce side effects throughout the body.
You likely qualify if…
You likely don't qualify if…
You will visit the hospital every 3 weeks for treatment. Depending on which group you're assigned to, you'll either receive the immunotherapy through a needle or small tube placed directly into or near your tumor (a procedure that takes about 5–10 minutes), or through a standard vein infusion (about 30 minutes), along with chemotherapy medication. You'll have blood tests before each treatment and regular imaging scans to check how the cancer is responding. The trial will continue for as long as the treatment is helping and you are tolerating it well.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China